Tag Archives: Pandemic

U.S. judge blocks expulsions of unaccompanied children under Trump’s pandemic-related border rules

By Ted Hesson and Mica Rosenberg

WASHINGTON (Reuters) – A U.S. district court judge on Wednesday blocked expulsions of unaccompanied children caught crossing into the United States, a setback for the outgoing Trump administration, which said the policy was aimed at limiting the spread of the coronavirus.

U.S. District Judge Emmet Sullivan in the District of Columbia ruled that the minors were likely to suffer irreparable harm because they could be subject to sexual abuse and other violence, as well as face the possibility of torture and death if summarily returned to their home countries.

President Donald Trump has made immigration curbs a central part of his four-year term in office and enacted a series of sweeping immigration restrictions during the pandemic.

President-elect Joe Biden, has vowed to reverse many of the Republican president’s hardline immigration policies.

Biden has not yet commented on how he would handle the emergency border rules that allow for rapid deportations. A Biden campaign official told Reuters that he would defer to health experts on such restrictions.

A U.S. Border Patrol official said in a September court filing that 8,800 unaccompanied minors were expelled under the border rules between their enactment on March 20 and Sept. 9.

Overall, the United States has expelled roughly 197,000 migrants caught crossing the U.S.-Mexico border from March through the end of September, though those figures include migrants who may have crossed multiple times.

Lee Gelernt, an attorney with the American Civil Liberties Union (ACLU), which represented plaintiffs in the lawsuit, said the policy was a “pretext” for Trump to close the border to children and asylum seekers from Central America.

The U.S. Department of Justice, U.S. Department of Homeland Security and White House did not immediately respond to requests for comment.

(Reporting by Ted Hesson in Washington and Mica Rosenberg in New York; Editing by Chizu Nomiyama and Nick Macfie)

New York City holds off school closure as U.S. braces for virus-stricken winter

By Gabriella Borter and Anurag Maan

NEW YORK (Reuters) – New York City schools were set to remain open for at least another day despite a rising COVID-19 case count, the mayor said on Tuesday, as surging infections and hospitalizations in the United States from coast to coast prompted new restrictions and predictions of a difficult winter ahead.

New York, home to the nation’s largest school district, reported a 7-day positive COVID-19 test rate of 2.74% on Tuesday – more than double what it was over the summer, but below the 3% threshold that Mayor Bill de Blasio set for keeping schools open.

“Everyone’s been participating in the things that have kept schools safe. Everyone has been wearing their masks … and we need to keep doing that to do our very, very best to keep schools open,” de Blasio told reporters on Tuesday.

“We have some new challenges because of what’s going on around us,” he added.

Beyond New York City, which was the epicenter of the U.S. COVID-19 crisis in the spring, infections have reached unprecedented levels nationwide.

Forty-one U.S. states have reported record increases in COVID-19 cases in November, while 20 have seen a record rise in deaths and 26 reported record hospitalizations, according to a Reuters tally of public health data. Twenty-five states reported test positivity rates above 10% for the week ending on Sunday, Nov. 15. The World Health Organization considers a positivity rate above 5% to be concerning.

The Midwest remains the hardest-hit U.S. region. It reported 444,677 cases in the week ending on Monday, Nov. 16, 36% more than the combined cases of the Northeast and West regions.

The number of coronavirus patients hospitalized in the United States hit a record of 73,140 on Monday. Hospitalizations have increased over 46% in past 14 days, according to a Reuters tally.

New York is among several northeast states that had managed to contain the virus fairly well over the summer after a frightening spring wave, but now has one of the highest week-over-week case increases as of Sunday.

Infections have also jumped in neighboring Connecticut by more than 50% in the last week from the week prior.

“Right now we see the storm clouds coming again,” Connecticut Governor Ned Lamont, a Democrat, told MSNBC in an interview on Tuesday.

Governors of several states and city officials have imposed new restrictions on indoor gatherings in recent days in an attempt to stem the spread of the disease over the winter, with the prospect of a widely available, effective vaccine still months away.

Several have urged citizens to exercise caution around the Thanksgiving holiday and not travel or socialize with extended family for the traditional indoor feast.

“I know this is difficult & frustrating, especially with the holidays right around the corner,” Vermont Governor Phil Scott wrote on Twitter on Tuesday, referring to his ban on multihousehold gatherings. “But it’s necessary & we need your help to get this back under control.”

(Reporting by Gabriella Borter and Anurag Maan; Additional reporting by Susan Heavey and Maria Caspani; Editing by Bill Berkrot)

Amazon launches online pharmacy in new contest with drug retail

By Jeffrey Dastin

(Reuters) – Amazon.com Inc. on Tuesday launched an online pharmacy for delivering prescription medications in the United States, increasing competition with drug retailers such as Walgreens, CVS Health and Walmart.

Called Amazon Pharmacy, the new store lets customers price-compare as they buy drugs on the company’s website or app. Shoppers can toggle at checkout between their co-pay and a non-insurance option, heavily discounted for members of its loyalty club Prime.

The move builds on the web retailer’s 2018 acquisition of PillPack, which Amazon said will remain separate for customers needing pre-sorted doses of multiple drugs.

Shares of pharmacy chains, drug wholesalers and grocers fell before the bell. Amazon’s shares were up nearly 2% at $3,190.99.

Over the past two years, Amazon has worked to secure more state licenses for shipping prescriptions across the country, which had been an obstacle to its expansion into the drug supply chain, according to analyst notes from Jefferies Equity Research.

The company founded as an online bookseller has disrupted industries including retail, computing and now potentially pharmaceuticals, drawing criticism of its size and power from labor groups and lawmakers along the way.

TJ Parker, PillPack’s CEO and vice president of Amazon Pharmacy, said in a statement the retailer aimed to bring “customer obsession to an industry that can be inconvenient and confusing.”

The company faces entrenched competition from Walgreens Boots Alliance Inc, CVS Health Corp, Walmart Inc, Rite Aid Corp., Kroger Co and others. Take-up of online ordering of drugs has been low, according to market research from J.D. Power.

Amazon injects a new look and feel into a space that has been dominated by a few large mail order pharmacies like CVS, Cigna Corp and UnitedHealth’s Optum, analysts from brokerage Evercore ISI said in a note.

“Consumers have historically not warmed to mail delivery of prescriptions, as customer service has been a weaker point of this service,” they added.

Shares of Walgreens Boots Alliance, Rite Aid and CVS tumbled between 8% and 12%, while those of drug distributors Mckesson Corp., Cardinal Health Inc. and Amerisourcebergen Corp were down 2% to 5%.

Should Prime members prefer buying in person, Amazon said its discounts on non-insurance purchases apply at more than 50,000 brick-and-mortar pharmacies – including those run by rivals. Inside Rx, a subsidiary of Cigna’s Evernorth, administers that benefit, Amazon said.

Still, the pandemic may help bring drug orders online. E-commerce has surged this year as governments told people to stay home to stave off infections of COVID-19, and Prime members – more than 150 million globally – may be receptive to buying medication online now that it’s from Amazon.

The company said Prime subscribers get up to 80% off generic and up to 40% off brand drugs when they pay without insurance, as well as two-day delivery.

Amazon’s online pharmacy is not yet available in Illinois, Minnesota, Louisiana, Kentucky, and Hawaii, a spokeswoman said.

(Reporting By Jeffrey Dastin in San Francisco and Caroline Humer in New York; Additional reporting by Manojna Maddipatla and Ankur Banerjee in Bengaluru; Editing by Lincoln Feast and Sriraj Kalluvila)

Breakthrough COVID vaccine tech could help defeat other diseases

By John Miller and Ludwig Burger

ZURICH/FRANKFURT (Reuters) – Breakthrough technology that transforms the body into a virus-zapping vaccine factory is poised to revolutionize the fight against COVID-19 but future pandemics and even cancer could be next, scientists say. The initial success of so-called messenger ribonucleic acid (mRNA) vaccines in late-stage trials by Moderna as well as Pfizer and its German partner BioNTech is the first proof the concept works.

Both experimental vaccines had efficacy rates above 90% based on interim findings, which was far higher than expected and well above the 50% threshold U.S. regulators insist upon for vaccines.

Now scientists say the technology, a slow-motion revolution in the making since the discovery of mRNA nearly 60 years ago, could speed up the development of new vaccines.

The traditional method of creating vaccines – introducing a weakened or dead virus, or a piece of one, to stimulate the body’s immune system – takes over a decade on average, according to a 2013 study. One pandemic flu vaccine took over eight years while a hepatitis B vaccine was nearly 18 years in the making.

Moderna’s vaccine went from gene sequencing to the first human injection in 63 days.

With BioNTech and Pfizer’s COVID-19 candidate on a similar trajectory, both could win regulatory approval this year, barely 12 months since the coronavirus first emerged.

Other companies are pursuing the technology such as Germany’s CureVac also has an mRNA vaccine candidate, though has yet to start a late-stage trial and is hoping it will get the green light after July 2021. “We’ll look back on the advances made in 2020 and say: ‘That was a moment when science really did make a leap forward’,” said Jeremy Farrar, director of the Oxford University Clinical Research Unit, which is backed by the Wellcome Trust.

THE LAST LAUGH

Discovered in 1961, mRNA carries messages from the body’s DNA to its cells, telling them to make the proteins needed for critical functions, such as coordinating biological processes like digestion or fighting disease.

The experimental vaccines from Moderna as well as Pfizer and BioNTech use lab-made mRNA to instruct cells to make the coronavirus’s spike proteins, which spur the immune system into action without replicating like the actual virus. Back in 1990, scientists managed to get mice to generate proteins by injecting mRNA, an early sign of the technology’s potential.

But early proponents such as Katalin Kariko, a Hungarian-born scientist and senior vice president at BioNTech, were hampered by obstacles such as mRNA’s instability in the body and its propensity to cause inflammatory responses.

A breakthrough came around 2005 when Kariko, along with colleagues at the University of Pennsylvania, figured out how to deliver mRNA without kicking the immune system into overdrive.

Still, it took another 15 years – and a pandemic that brought the world’s economy to its knees – to reach the cusp of success. Kariko said her years of dogged pursuit once made her the butt of jokes for some university colleagues.

“The last time they laughed at me and ridiculed me was when they learned that I was going to join BioNTech seven years ago and they realized this company (didn’t) even have a website,” she told Reuters. “But now, they learn of BioNTech and that we can do good things.”

Kariko said her life’s work could pay dividends, not just against COVID-19, but other diseases.

“It could be easier sailing for the next anti-viral product, a vaccine for influenza and other infectious disease,” said Kariko, whose daughter is a U.S. Olympic gold medalist rower.

CANCER NEXT?

Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines.

BioNTech is testing an anti-melanoma mRNA with Swiss pharmaceutical giant Roche in a Phase II trial.

Among Moderna’s most advanced projects, besides its COVID-19 vaccine, are mRNA compounds to treat ovarian cancer or Myocardial ischemia, which are also in the second test phase.

None of the potential mRNA cancer therapies have reached the critical large-scale Phase III trials, however, and Kariko acknowledges that cancer presents a bigger challenge.

While a virus is a foreign intruder, cancer cells, however malignant, come from within the body, making them tougher to seek out and expose so they can be attacked.

“Sometimes cancer is just caused by gene and chromosome duplication and then everything about it looks normal and the cell is just dividing more than it should,” she said.

For vaccines against infectious diseases, the pharmaceutical industry’s traditional approach has been to whip them up in large bioreactors, a time-consuming, expensive process in facilities that can cost up to $700 million to build.

By contrast, Zoltan Kis, an Imperial College London researcher who models vaccine manufacturing, estimates that one five-liter bioreactor inside a $20 million facility could make a billion doses of some kinds of mRNA vaccines a year.

Drug manufacturer Lonza, enlisted to make ingredients for 400 million doses of Moderna’s vaccine annually at U.S. and Swiss sites, is due to start production this year with manufacturing lines costing $60 million to $70 million each.

“We are producing mRNA at smaller scales and in smaller facilities when compared to traditional larger-scale equipment and facilities,” Andre Goerke, Lonza’s global lead for the Moderna project, told Reuters. “The manufacturing ramp-up is quicker and more economical.”

‘ULTRA-FAST RESPONSE’

Raymond Schiffelers, of University Medical Center Utrecht in the Netherlands, who heads a European Union program for mRNA therapeutics, said the major advantage of the technology was that vaccine developers could mount an “ultra-fast response”.

“Within weeks, testing can start, a major advantage over conventional vaccines,” he said.

The moment a pathogen’s genomic sequence is known, synthetic mRNAs can be designed that encode key parts of the virus, such as the coronavirus’s potentially lethal spike protein.

Risks and challenges for mRNA remain.

Some candidates must be stored at extremely cold temperatures, making delivery potentially difficult in countries with limited infrastructure. They also may be fragile to transport, Schiffelers said.

BioNTech’s vaccine, for example, must be transported at minus 70 degrees Celsius, though Moderna said on Monday it can ship its candidate in normal refrigerators.

Francis Collins, director of the U.S. National Institutes of Health (NIH), which funded Moderna’s vaccine development, also said mRNA vaccines may not be a silver bullet for flu, since it mutates so swiftly that reaching 90% efficacy is unlikely.

But for COVID-19, Collins said mRNA is likely to be a revolution.

“It’s clearly several months faster than any of the other methods,” Collins said. “In a crisis moment, several months really matter.”

(Reporting by John Miller in Zurich, Allison Martell in Toronto, Ludwig Burger in Frankfurt, Kate Kelland in London, Michael Erman in New York, Julie Steenhuysen in Chicago and Marton Dunai in Budapest; Editing by Josephine Mason and David Clarke)

Travel restrictions challenge vaccine rollout, airlines warn

PARIS (Reuters) – Air cargo operators may struggle to distribute new COVID-19 vaccines effectively unless pandemic travel restrictions are eased, global airlines cautioned on Monday.

The warning came in vaccine transport guidelines issued by the International Air Transport Association (IATA), which is pushing governments to replace travel curbs and quarantines with testing.

“If borders remain closed, travel curtailed, fleets grounded and employees furloughed, the capacity to deliver life-saving vaccines will be very much compromised,” the IATA document said.

Moderna Inc. said on Monday its experimental COVID-19 vaccine had proved 94.5% effective in a clinical trial, a week after rival drugmaker Pfizer reported 90% efficacy findings for its vaccine. Once approved, both vaccines are likely to require transport and storage well below freezing, posing logistical hurdles.

Widespread grounding of passenger flights that normally carry 45% of global cargo in their holds has taken out capacity, thinning the air freight network and driving up prices.

Existing immunization campaigns have struggled with the partial shutdown. The World Health Organization and UNICEF “have already reported severe difficulties in maintaining their planned vaccine programs during the COVID-19 crisis due, in part, to limited air connectivity,” IATA said.

Vaccines will need to be shipped to developing countries reliant on passenger services for cargo, IATA’s head of cargo Glyn Hughes told Reuters. Even in industrialized states, vaccine dispersal may be a tighter bottleneck than production, requiring shipments to secondary airports on passenger jets.

In preparation for the challenge of mass vaccine distribution, governments should move to reopen key passenger routes backed by robust testing, the airline body argues.

“There are several more months for governments to go through the planning cycle,” Hughes said, leaving enough time to “get passenger networks safely resumed, looking at safe travel corridors (and) mutual acceptance of testing procedures.”

(Reporting by Laurence Frost; editing by David Evans)

U.S. COVID-19 cases cross 11 million as pandemic intensifies

By Roshan Abraham and Seerat Gupta

(Reuters) – The number of coronavirus cases in the United States crossed the 11-million mark on Sunday reaching yet another grim milestone, according to a Reuters tally, as the third wave of COVID-19 infections surged across the country.

Reuters data shows the pace of the pandemic in the United States has quickened, with one million more new cases from just 8 days ago when it hit 10 million, making it the fastest since the pandemic began. This compares with 10 days it took to get from 9 to 10 million and 16 days it took to reach 9 million from 8 million cases.

The United States, hardest-hit by the coronavirus, crossed 10 million COVID-19 cases on November 8 and is reporting over 100,000 daily cases for the past 11 days straight.

The latest 7-day average, shows the United States is reporting more than 144,000 daily cases and 1,120 daily deaths, the highest for any country in the world.

Texas and California have reported the highest number of COVID-19 infections across the United States, together accounting for about 2.1 million cases or about 19% of the total cases since the pandemic began, according to Reuters analysis.

As COVID-19 related hospitalizations continue to rise, crossing 69,000 on Saturday, U.S. President-elect Joe Biden’s top advisers have stressed the need to control the pandemic, warning that local healthcare systems are at a tipping point.

The Midwest remains the hardest-hit region based on the most cases per capita with North Dakota, South Dakota, Wisconsin, Iowa and Nebraska the top five worst-affected U.S. states.

Illinois, which has emerged as the pandemic’s new epicenter in the region as well as across the country, reported a record 15,433 new cases on Friday, the most of any state in a 24-hour period, surpassing the previous all-time high of 15,300 set by Florida in July.

Several states this week re-imposed restrictions to curb the spread of the virus across the nation. North Dakota became the latest state to require that face coverings be worn in public, as it joins 39 other states this month in reporting record daily jumps in new cases.

State governors urged residents to stay home as much as possible, including Nevada Democrat Steve Sisolak, who said late on Friday that he became the fourth governor to become infected with the virus.

The United States accounts for about 20% of more than 54 million global cases and close to 19% of the 1.31 million deaths reported worldwide, according to a Reuters tally.

(Reporting by Roshan Abraham and Seerat Gupta in Bengaluru; editing by Diane Craft)

Biden to spotlight economy as Trump vows more court challenges to election

By Trevor Hunnicutt and John Whitesides

WILMINGTON, Del./WASHINGTON (Reuters) – President-elect Joe Biden on Monday will focus on reviving a pandemic-battered U.S. economy as he prepares to take office, while outgoing President Donald Trump has promised more lawsuits of the type that so far have failed to alter his election defeat.

With coronavirus cases surging, Biden will receive a briefing and give a speech in his home state of Delaware on rebuilding an economy that has suffered millions of job losses as the pandemic has killed more than 245,000 Americans.

Biden’s scientific advisers will meet this week with pharmaceutical companies developing vaccines to prevent COVID-19, a top aide to the president-elect said, in preparation for the logistical challenges of widespread vaccination after the Democrat takes office on Jan. 20.

Trump, a Republican, briefly appeared to acknowledge defeat on Sunday only to backtrack, saying on Twitter that he concedes “nothing” and repeating his unfounded accusations of voter fraud.

He later promised on Twitter to file “big cases showing the unconstitutionality of the 2020 Election,” even though he has made no headway with his legal challenges in multiple states so far.

Election officials from both parties have said there is no evidence of major irregularities. Federal election security officials have decried “unfounded claims” and expressed “utmost confidence” in the integrity of the elections, according to a statement last week by the lead U.S. cybersecurity agency.

LEGAL SETBACK

In another blow to Trump’s legal strategy, his campaign on Sunday dropped a major part of a lawsuit it had brought seeking to prevent Pennsylvania from certifying its results, narrowing the case to an issue affecting a small number of ballots. Biden won the state by more than 68,000 votes.

Biden beat Trump in the Nov. 3 election by the same 306-232 margin in the state-by-state Electoral College that Trump proclaimed a “landslide” when he won in 2016. The former vice president also won the national popular vote by at least 5.5 million votes, or 3.6 percentage points, with ballots still being counted.

Former President Barack Obama, a Democrat who campaigned against Trump, said it was past time for Trump to concede, and criticized Republicans who also refuse to accept the victory of his former vice president.

“When your time is up, then it is your job to put the country first and think beyond your own ego,” Obama told the CBS News show “60 Minutes” in an interview that aired on Sunday.

“I’m more troubled by the fact that other Republican officials who clearly know better are going along with this.”

The Senate Judiciary Committee, which is chaired by Republican Senator Lindsey Graham, one of Trump’s most loyal supporters, will hold a hearing on Tuesday titled: “Breaking the News: Censorship, Suppression and the 2020 Election.”

STILL NO CONCESSION

The Trump administration has still not recognized Biden as president-elect, preventing his team from gaining access to the government office space and funding normally provided to an incoming administration.

Biden’s top advisers said Trump’s refusal to begin a transition could jeopardize the battle against the virus and inhibit vaccine distribution planning.

The number of U.S. coronavirus cases passed 11 million on Sunday, up a million in a week and the fastest increase since the pandemic began.

Biden has promised to make the health crisis a top priority as president. Ron Klain, who will be White House chief of staff when Biden takes office, said Biden’s scientific advisers would meet with Pfizer Inc and other unnamed drugmakers this week.

Pfizer said last week its vaccine candidate had proved more than 90% effective in initial trials, giving hope that widespread vaccination in the coming months could help get the pandemic under control.

Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial.

Other companies also are in advanced stages of developing promising vaccines.

Biden will also resume work on building his governing team. Although Klain, his first appointment, is a white man, the president-elect has vowed that his administration will “look like America” and be represented by women and minorities.

Some 46% of his transition staff are people of color and 52% are women, CNN reported, citing data provided by the transition team.

(Reporting by Trevor Hunnicutt in Wilmington and John Whitesides in Washington; Additional reporting by Susan Heavey, Jan Wolfe, David Shepardson, David Morgan and Daniel Trotta; Editing by Peter Cooney and Kevin Liffey)

Michigan, Washington state impose severe COVID-19 restrictions as U.S. infections soar

By David Shepardson and David Lawder

WASHINGTON (Reuters) – Michigan and Washington state on Sunday imposed sweeping new restrictions on gatherings, including halting indoor restaurant service, to slow the spread of the coronavirus as total U.S. infections crossed the 11 million mark, just over a week after hitting 10 million.

Michigan Governor Gretchen Whitmer ordered a ban on in-person high school and college classes as well as indoor dining service for three weeks starting on Wednesday as increasingly cold weather drives people indoors where the virus can spread more easily.

She banned public events at concert halls, casinos, movie theaters, skating rinks and other venues, while in-home gatherings will be limited to 10 people from no more than two households.

Whitmer, a Democrat, warned that without aggressive action, Michigan could soon suffer 1,000 COVID-19 deaths per week.

“We are in the worst moment of this pandemic to date,” she told a news conference. “The situation has never been more dire. We are at the precipice and we need to take some action.”

White House coronavirus adviser Scott Atlas reacted to the Michigan orders by urging state residents on Twitter to “rise up” against them. After this drew criticism from Michigan Attorney General Dana Nessel, Atlas said he “NEVER was talking at all about violence.”

Washington state Governor Jay Inslee, a Democrat, announced a one-month ban on indoor services at restaurants and gyms, and a reduction of in-store retail capacity to 25%.

Indoor gatherings would be prohibited outside of one’s household and outdoor gatherings would be limited to five people in Washington state under Inslee’s order.

The new restrictions come as daily new infections in recent days have more than doubled from single-day highs reported during the previous U.S. peak in mid-July. The number of COVID-19 patients in U.S. hospitals also has reached an all-time high.

‘DANGEROUS PERIOD’

Earlier on Sunday, U.S. President-elect Joe Biden’s top advisers called for urgent action to address COVID-19, warning that Republican President Donald Trump’s refusal to begin a transition of power could further jeopardize the battle against the rampaging virus. Biden’s advisers also said it would inhibit vaccine distribution planning and could jeopardize additional government financial aid before Biden, a Democrat, takes office in January.

“We are in a very dangerous period,” Dr. Michael Osterholm, a member of Biden’s COVID-19 Advisory Board and director of the University of Minnesota’s Center for Infectious Disease Research and Policy, told NBC News’ “Meet the Press.”

Unless action is taken now, “we’re going to see these numbers grow substantially,” Osterholm warned. “Our future’s in our hands.”

Basic public health measures such as face covering to curb the spread have become politicized under Trump, who has eschewed mask mandates even after contracting COVID-19 last month, while Biden has backed their widespread use.

Still, some Republican governors in recent days have been forced to act, with North Dakota joining 35 other states over the weekend in mandating masks and Iowa this week requiring them in certain circumstances.

Forty U.S. states have reported record increases in COVID-19 cases in November, while 20 saw a record rise in deaths and 26 reported record hospitalizations, according to a Reuters tally.

The latest 7-day average, shows the United States is reporting more than 144,000 daily cases and 1,120 daily deaths, the highest for any country in the world.

Ron Klain, Biden’s incoming White House chief of staff, on Sunday urged Congress to immediately pass COVID-19 relief legislation with new restrictions certain to take a toll.

“This could be a first example of bipartisan action post-election,” Klain told NBC. He said Biden has spoken to congressional Democratic leaders, but not to Senate Republican leader Mitch McConnell, who has refused to publicly acknowledge Biden as president-elect.

‘PASSING A BATON’

Klain said there had been no formal contact between Biden’s advisory panel and the White House Coronavirus Task Force, which requires transition authorization from the General Services Administration.

“It’s really important in the smooth handing over of the information,” top U.S. infectious disease expert and White House task force member Dr. Anthony Fauci told CNN’s “State of the Union” program. “It’s almost like passing a baton in a race, you don’t want to stop and give it to somebody, you just want to essentially keep going.”

Biden’s team this week planned to meet with Pfizer Inc., which last week released positive initial data on its experimental novel coronavirus vaccine, and other drugmakers, Klain said.

Former U.S. Surgeon General Dr. Vivek Murthy, head of Biden’s COVID team, told Fox News the coronavirus surge was “deeply alarming” but that a national lockdown was “a measure of last resort.”

“The better way to think about these safety restrictions is more a dial that we turn up and down depending on severity” in a given area, he said.

(Reporting by Susan Heavey and David Shepardson; additional reporting by Michelle Price, Nathan Layne, Sarah N. Lynch, Linda So and Anurag Maan; Writing by David Lawder; Editing by Bill Berkrot, Diane Craft, Robert Birsel)

Fauci not advising Biden, sees no reason to quit Trump now: Reuters interview

By Julie Steenhuysen

CHICAGO (Reuters) – Dr. Anthony Fauci, the top U.S. infectious disease expert, said he has had no contact with President-elect Joe Biden’s coronavirus transition team and sees no reason to quit to join that effort when there is so much to do now to fight the surging pandemic.

“I stay in my lane. I’m not a politician. I do public health things,” he said in an interview on Thursday ahead of next week’s Reuters Total Health conference.

Since January, Fauci has served on President Donald Trump’s White House Coronavirus Task Force, a position that has frequently put him at odds with the president, who has sought to downplay the pandemic and focused instead on opening the economy.

“There’s absolutely no reason and no sense at all for me to stop doing something in the middle of a pandemic that is playing a major role in helping us get out of the pandemic,” Fauci said.

His advice for the president-elect, he said, is “exactly the same” as what he is recommending now – social distancing, avoiding crowds, wearing masks, washing hands. “Public health principles don’t change from one month to another or from one administration to another.”

Fauci has served six administrations and came to prominence fighting the AIDS epidemic in the 1980s under President Ronald Reagan.

His “day job” is developing vaccines and therapeutics as director of the National Institute of Allergy and Infectious Diseases, work that is starting to bear fruit.

On Monday, Pfizer Inc and German partner BioNTech SE announced that their experimental coronavirus vaccine was more than 90% effective – significantly higher than most experts had anticipated.

Moderna Inc, a company developing a similar vaccine with support from the White House’s Operation Warp Speed program, is expected to report results from their late-stage vaccine trial in the next week or so.

Both vaccines use messenger RNA (mRNA) technology, an entirely new rapid vaccine platform that uses synthetic genes to trigger an immune response. Older methods typically use some form of inactivated or killed virus particles.

“It was a home run for the Pfizer product, more than 90% – close to 95% – effective. I have every reason to believe that the Moderna product is going to be similar,” Fauci said.

“It’s an almost identical platform to the Pfizer vaccine, so I would not be surprised at all if it was highly effective,” Fauci added.

The next big question about mRNA technology is safety. Fauci took as a good sign the fact that neither the Pfizer trial, which has enrolled more than 43,000 people so far, nor the Moderna trial, which involves 30,000, had to pause to investigate safety issues.

“That’s really good news,” he said. People in both trials will be followed for two years to make sure there are no long-term side effects. Barring that, “I think that the mRNA platform is here to stay,” he predicted.

In spite of the high bar set by the Pfizer vaccine so far, Fauci said he believes there is still “plenty of room for multiple vaccines, even though there may be a modest degree of difference in total efficacy.”

(Reporting by Julie Steenhuysen, Editing by Peter Henderson and Bill Berkrot)

Sewage testing could protect schools, hospitals from COVID-19 outbreaks

By Allison Martell

TORONTO (Reuters) – Early in the pandemic, a few cities and countries around the world began testing sewage for evidence of the coronavirus, hoping to detect rising infections early.

Now some researchers are fine-tuning that strategy by moving upstream to test waste from single hospitals or other buildings, aiming to quickly pinpoint burgeoning COVID-19 outbreaks and stop them with testing and isolation.

While the virus primarily spreads through droplets expelled from the mouth and nose, it can also be shed via human waste.

Testing sewage is cheaper and less invasive than swabbing hundreds of people, and it could be done more frequently. With the virus again surging across much of the world, schools, hospitals and care homes badly need to catch new cases early.

“What we’re trying to do is identify outbreaks before they happen,” said Francis Hassard, a lecturer at Cranfield University, part of a project that started collecting samples at 20 London secondary schools last month.

Hassard’s UK government-funded team will expand sampling to at least 70 schools. The program is a research project, meant to test the approach, and is not yet a full-fledged surveillance system.

In the Canadian province of Alberta, researchers at the University of Calgary have been gathering samples from three local hospitals, including the site of a recent outbreak in which 12 people died.

The team was still refining their methods when that outbreak began. When they went back to test wastewater, they found the amount of coronavirus genetic material rose 580% as the virus spread, said Kevin Frankowski, executive director of Advancing Canadian Wastewater Assets.

“We saw a very significant change,” said Frankowski. “It was really strong proof that this … approach works.”

The project shares data with Alberta Health Services, which runs the province’s hospitals. If levels spike again, they could respond by testing individuals or taking other steps to mitigate spread, depending on the situation, said Frankowski.

In the United States, professional services company GHD set up wastewater testing at a handful of university residences, and recently started advertising the service to long-term care homes, drawing significant interest, said Peter Capponi, a principal at GHD.

CLOSE TO THE SOURCE

So far, most sewage testing has been done at treatment plants. Dutch authorities publish a national statistic, based on samples from all over the country, and French authorities have cited similar data for months. The state of Ohio monitors water at treatment plants across the state.

However, it can take 24-to-36 hours for waste to arrive at a treatment plant, and heavy rain or industrial effluent can dilute samples.

When viral levels rise at a treatment plant, it is not always obvious what should be done. But when virus material suddenly appears in sewage leaving a single building, the path forward is more clear.

At the University of Arizona, for example, sewage from one residence turned positive on August 25. The next day, the university began testing students. Two tested positive and were isolated, heading off what could have been an outbreak, the school said in a release.

With most of these efforts in early stages, it is not yet clear how well the approach will work at scale.

Not every infected person sheds virus in their waste, and there is some disagreement among researchers on how early in the course of COVID-19 that shedding begins on average.

Human behavior can affect data collection. Do enough children use the bathroom at school to generate good data? The virus does not show up in urine, just solid waste.

There are also logistical issues.

“Buildings have multiple discharge points,” said GHD’s Capponi. “Some of them are not accessible. Some may show up on a design drawing, but were not constructed that way.”

Outside the controlled environment of a treatment plant, sewage is less uniform. Sampling equipment can get clogged with toilet paper and other debris, said Hassard.

And a single “grab” sample might miss the virus. The UK project collects throughout the school day.

Higher-tech auto-samplers can collect waste over a longer period, but are in increasingly short supply as more testing programs ramp up.

MilliporeSigma, a unit of Germany’s Merck KGaA, makes the Centricon P-70 filter used on some waste samples.

The company has doubled production, a spokeswoman said, after an “unprecedented surge in demand” from governments hoping to test for the virus.

(Reporting by Allison Martell in Toronto; Edilting by Caroline Humer and Bill Berkrot)